Melanoma Insights for Professionals

In our final episode of our special vodcast series, RedefiningImmunotherapy: Lessons from Melanoma, our experts discuss the future of immunotherapy, separating hype from reality and exploring the next frontier of cancer treatment.
From cellular therapies and personalised cancer vaccines tomRNA technology and biomarker-driven treatment selection, the panel examines the innovations that could reshape melanoma care over the next decade and the challenges that remain before these therapies become routine clinical practice.
Led by Prof Georgina Long AO, the panel of experts discuss:
why melanoma continues to lead the globalimmunotherapy revolution
the promise and limitations of TIL therapy,TCR-T cells and other cellular therapies
how mRNA technology could transform cancertreatment beyond vaccines
the rise of personalised cancer vaccines
why biomarkers will be critical to the future ofprecision immunotherapy.
Be sure to take a look at our earlier episodes from this series.
This special edition vodcast from ⁠Melanoma Institute Australia⁠ is suitable for Medical Oncologists, Oncology Nurses and other health professionals.
SPEAKERS
Prof Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
A/Prof Ines Silva - Medical Oncologist, Melanoma Institute Australia
A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of Sydney

Please note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.
This special vodcast is an initiative of ⁠⁠Melanoma Institute Australia⁠⁠ and made possible by an unrestricted educational grant from Bristol Myers Squibb.
For more practise-changing education, visit MIA's ⁠⁠Melanoma Education Portal⁠⁠.

In our fourth episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts discuss one of the most rapidly evolving areas in melanoma care: immunotherapy treatment strategy.
Drawing on decades of combined clinical experience, the panel explores how treatment paradigms are shifting from decisions around monotherapy versus combination immunotherapy, to increasingly nuanced conversations about treatment duration, rechallenge after progression and retreatment following toxicity.
Led by Prof Georgina Long AO, the panel of experts deliver candid expert debate, practical insights and clinical nuance as they explore the evolving landscape of immunotherapy treatment decisions in melanoma care. The panel discusses:     
when to stop immunotherapy and why less treatment may sometimes be enough
how PET complete metabolic response (CMR) is influencing treatment duration decisions
rechallenge strategies after progression or immune-related toxicity
managing patients after ipilimumab/nivolumab toxicity
the growing move from adjuvant to neoadjuvant treatment approaches.
The discussion also tackles the biology behind durable immune responses, the role of surveillance imaging, and the emerging concept of “definitive immunotherapy”, highlighting how melanoma continues to lead the way in reshaping cancer care.
Be sure to take a look at our earlier episodes from this series.
This special edition vodcast from Melanoma Institute Australia is suitable for Medical Oncologists, Oncology Nurses and other health professionals.
SPEAKERS
Prof Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
A/Prof Ines Silva - Medical Oncologist, Melanoma Institute Australia
A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
Please note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.
This special vodcast is an initiative of ⁠Melanoma Institute Australia⁠ and made possible by an unrestricted educational grant from Bristol Myers Squibb.
For more practise-changing education, visit MIA's ⁠Melanoma Education Portal⁠.

Here's a sneak peak for our upcoming episode of Redefining Immunotherapy: Lessons from Melanoma. In this episode, our experts discuss one of the most rapidly evolving areas in melanoma care: immunotherapy treatment strategy.
Look out for Episode 4, Melanoma Treatment Strategy: Expert Perspectives, dropping on Monday 1 June.

In our third episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts focus on one of the most important challenges in modern cancer care: immunotherapy toxicity.
From subtle early warning signs to life-threatening immune-related adverse events, this episode explores how clinicians can better predict, recognise and manage toxicity while still maximising the life-saving potential of immunotherapy.
Led by Prof Georgina Long AO, the panel of experts share real-world insights from decades of combined experience, including:
how to educate patients to improve early reporting of symptoms
when to pause treatment and why "less can be more"
practical approaches to managing colitis, hepatitis, pneumonitis and neurological toxicities
the evolving role of steroids, infliximab and targeted immunosuppression
why early intervention can improve both quality of life and survival outcomes.
Packed with nuanced clinical discussion, relatable patient scenarios and candid expert debate, this episode delivers valuable insights for healthcare professionals using immunotherapy across melanoma and other cancer settings.
Be sure to take a look at our earlier episodes from this series.
This special edition vodcast from Melanoma Institute Australia is suitable for Medical Oncologists, Oncology Nurses and other health professionals.
SPEAKERS
Prof Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
A/Prof Ines Silva - Medical Oncologist, Melanoma Institute Australia
A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
Please note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

This special vodcast is an initiative of Melanoma Institute Australia and made possible by an unrestricted educational grant from Bristol Myers Squibb.

For more practise-changing education, visit the Melanoma Education Portal.

In our second episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts tackle one of the biggest challenges in modern oncology: how do we make smarter immunotherapy decisions for individual patients?
The panel explores the real-world factors that shape treatment selection in advanced melanoma; from tumour burden, brain and liver metastases, and BRAF mutation status, to patient age, fitness and comorbidities. They unpack the evolving role of combination immunotherapy,including PD-1 monotherapy, ipilimumab/nivolumab and newer LAG-3 combinations, while weighing the balance between efficacy and toxicity.
The discussion also dives into the promise and limitationsof biomarkers such as PD-L1, tumour mutational burden (TMB), interferon gamma signatures and MSI-high status, and examines why predicting response to immunotherapy remains one of the field’s greatest challenges.
Blending practical clinical insight with emerging research,this episode offers a thoughtful and highly relevant discussion on personalising immunotherapy in the pursuit of more durable outcomes, and ultimately, cure.

This vodcast is suitable for Medical Oncologists, Oncology Nurses and other health professionals.

SPEAKERS
Prof Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of Sydney
A/Prof Ines Silva - Medical Oncologist, Melanoma Institute Australia
A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of Sydney

Please note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

This special vodcast is an initiative of Melanoma Institute Australia and was made possible by an unrestricted educational grant from Bristol Myers Squibb.